幽门螺杆菌热休克蛋白A亚单位编码基因的克隆与序列分析

目的 幽门螺杆菌(Helicobacter pylori)热休克蛋白A亚单位的编码基因(hspA)克隆和序列分析，为H.pyiori基因工程疫苗的研究奠定基础。方法 应用PCR方法获得国内分离H.pylori菌株MEI，HP27和国际标准参考株H.pylori的hspA基因，通过定向克隆的方法分别插入克隆载体pNEB193中，用质粒酶切电泳和特异PCR方法鉴定重组质粒。克隆基因经测序后进行核苷酸和氨基酸的同源性比较。结果 重组质粒经双酶切后得到0．35kb的hspA基因片段，特异PCR可扩增出hspA基因片段，证实H.pylori hspA基因的重组克隆质粒构建成功。经测序，国内分离HpMEL-HP27的hspA基因全长357bp(Genbank收录号：AY295084)，编码由118个氨基酸残基组成的肽链，hspA基因序列与GenBank公布的H.pylorl相应基因同源性高达95．20％～97．48％，氨基酸序列同源性在95．76％～97．46％之间。结论 克隆了H．pylori菌株MEL-HP27的hspA基因，其核酸序列与国际参考株NCTC11637同源性为97．48％。     

幽门螺杆菌外膜蛋白18的克隆表达及纯化研究

目的克隆表达幽门螺杆菌（HP）外膜蛋白,为HP的疫苗开发及诊断试剂盒的研究奠定基础。方法用PCR方法从HP临床分离株9806的染色体DNA中扩增出OMP18基因片段,将目的基因插入表达载体pQE30中,重组载体pQE30-OMP18经DNA测序鉴定后,将重组质粒转化大肠杆菌E．coli．M15,IPTG诱导表达。采用镍离子亲和层析纯化蛋白,并用SDS-PAGE和Western blot分析鉴定其表达。结果PCR扩增出长度为537bp的OMP18基因,片段测序分析其与Gen—Bank公布的核苷酸序列相似性达99％;SDS—PAGE显示,重组工程菌经IPTG诱导表达了分子量为20．0kDa的目的蛋白,占总蛋白的20％,经纯化后,目的蛋白纯度达85％以上;Western blot结果表明,该蛋白可与兔抗HP的多克隆抗血清发生特异的抗原抗体结合反应。结论成功构建了OMP18表达载体pQE30-OMP18,并在大肠杆菌中获得高效表达,为HP疫苗有效抗原筛选及诊断试剂的开发奠定基础。     

志贺毒素B(ShT-B)亚单位在两种表达载体中表达形式的分析

用KpnⅠ和HindⅢ双酶切pGEM -TB3 克隆质粒 ,得到为大小约为 2 2 5bp的ShT -B基因片段 ,分别将其插入到经双酶切的 pQE4 0和 pQE30表达载体中 ,构建了两个ShT -B的重组表达质粒pQE4 0 -B3 和 pQE30 -B2 ,分别转化到E .coliM15。经IPTG诱导后 ,重组质粒目的蛋白均得到表达。其中 ,pQE4 0 -B3 和pQE30 -B2 ,分别化到E .coliM 15 ,经IPTG诱导后 ,重组质粒目的蛋白均得到表达。其中 ,pQE4 0 -B3 表达蛋白约占菌体总蛋白的 37% ,主要为包涵体形式。pQE30 -B2 表达蛋白约占菌体总蛋白的 16 % ,主要为可溶性形式 ,约 9 2 %。为重组抗原的制备提供了必要的物质基础。     

幽门螺杆菌尿素酶B亚单位编码基因的克隆与序列分析

目的 幽门螺杆菌(Helicobacter pylori)尿素酶B亚单位的编码基因(ureB)的克隆和序列分析，为H．pylori基因工程疫苗的研究奠定基础。方法应用PCR方法获得国内分离H．pylori菌株MEI，HP27和国际标准参考株H．pylori的ureB基因，通过定向克隆的方法分别插入克隆载体pNEB193中，用质粒酶切电泳和特异PCR方法鉴定重组质粒。克隆基因经测序后进行核苷酸和氨基酸的同源性比较。结果 重组质粒经双酶切后得到1．71kb的ureB基因片段，特异PCR可扩增出ureB基因片段，证实H．pylori ureB基因的重组克隆质粒构建成功。经测序，国内分离H．pylori MEL-HP27的ureB基因全长1710bp( Genbank收录号：AY295085)，编码由569个氨基酸残基组成的肽链，ureB基因序列与GenBank公布的H．pylori相应基因同源性高达96．08％～98．30％，氨基酸序列同源性在98．77％．99．82％之间。结论 成功克隆了MEL-HP27菌株的ureB基因，其核苷酸序列与国际参考株NCTC11637的同源性为97．67％。     

以白细胞介素-2为免疫佐剂的幽门螺杆菌尿素酶B亚单位核酸疫苗的构建及其免疫保护作用

背景：细胞因子具有免疫佐剂效应，但将其用作幽门螺杆菌（H．pylori）核酸疫苗佐剂的研究报道尚少。目的：构建同时含H．pylori尿素酶B亚单位（ureB）基因和小鼠白细胞介素-2（IL-2）基因的重组活减毒鼠伤寒沙门菌核酸疫苗，体外鉴定其表达蛋白的免疫原性，体内检测其对H．priori感染的免疫保护作用。方法：以聚合酶链反应（PCR）扩增H．priori ureB基因和小鼠IL-2基因，分别插入pUCmT载体，测序，通过一系列酶切、连接反应分别克隆人真核表达载体pIRES，酶切、PCR鉴定；重组质粒pIRES-ureB和pIRES-ureB-IL-2分别转化减毒鼠伤寒沙门菌LB5000，抽提质粒，进一步转化终宿主菌SL7207，反复传代培养。以Lipofectamine^TM2000将重组质粒分别体外转染COS-7细胞，蛋白质印迹法检测表达蛋白的免疫原性。以疫苗菌经口接种小鼠，4周后予H．pylori攻击，攻击后4周鉴定H．pylori感染状况。结果：测序结果显示扩增出的ureB和IL-2基因序列与GenBank中的H．pylori ureB和小鼠IL-2序列一致，酶切、PCR鉴定证实ureB和IL-2基因已克隆人pIRES载体，并成功构建了稳定的含H．pylori ureB和小鼠IL-2基因的重组活减毒鼠伤寒沙门菌核酸疫苗。蛋白质印迹法显示，pIRES-ureB-IL-2转染的COS-7细胞表达特异性UreB和IL-2蛋白。体内实验显示，疫苗接种组小鼠的免疫保护率显著高于PBS对照组（P〈0．01），其中ureB-IL-2疫苗组又显著高于ureB疫苗组（87．5％对62．5％，P〈0．05）。结论：成功构建了编码H．pylori ureB和免疫佐剂IL-2基因的重组活减毒鼠伤寒沙门菌核酸疫苗，体外实验证实其可表达具有免疫原性的抗原蛋白和佐剂蛋白，体内实验证实其对小鼠H．pylori感染具有免疫保护性，免疫佐剂IL-2可提高核酸疫苗的免疫保护率。     

幽门螺杆菌47kDa微孔蛋白基因的克隆表达及特性鉴定

目的对人幽门螺杆菌(H.pylori)编码47kDa外膜微孔蛋白基因omp47克隆表达及特性鉴定,探索研制H.pylori疫苗的新途径。方法培养和收集H.pylori标准菌株NTTC11637及临床菌株,采用酚∶氯仿抽提、纯化基因组DNA。设计上下游引物,并以该基因组为模板,采用聚合酶链反应(PCR)扩增omp47基因片断。将目的基因和与克隆载体PGEM-T连接后,转化至E.coli DH5α及BL21,碱裂解提取质粒经BamHI和XhoI双酶切鉴定并进行序列分析。重组蛋白采用IPTG诱导表达后,经SDS-聚丙烯酰胺凝胶电泳(PAGE)鉴定、镍亲和层析纯化检测抗原活性。结果经酶切、测序分析表明,插入的基因片断为1284bp,编码427个氨基酸。与GenBank公布的H.pylori标准株26695、43504及J99序列比对,核苷酸同源性高达94%~96%,编码氨基酸同源性96%~99%。经SDS-PAGE检测,电泳图谱上显示一条相对分子量为47kda的新生蛋白带。Western blot检测表明重组蛋白有较好的抗原性。结论成功克隆了外膜微孔蛋白OMP47的编码基因,为H.pylori疫苗的研制和试剂盒的开发奠定了良好的基础。     

编码刚地弓形虫棒状体蛋白2与主要表面抗原1基因的克隆和表达

目的 构建编码弓形虫RH株棒状体蛋白2（ROP2）和主要表面抗原1的重组表达质粒，纯化和复性的融合蛋白为弓形虫病快速诊断试剂盒及蛋白质疫苗的研制作准备。方法 用PCR技术从弓形虫基因组DNA中扩增出ROP2和P30基因片段，分别克隆人pMDl8-T载体，并对重组人外源基因的质粒通过PCR、双酶切和测序鉴定，将pMD-ROP2中RoP2基因片段经EcoRI和HindⅢ酶切、连接等反应，亚克隆入pET-30a（＋）原核表达载体，构建pET-ROP2载体，然后再将pMD-P30中的P30基因片段与经同样NcoI和EcoRI酶切的pET-30a（＋）载体连接，经含卡那霉素的LB平板筛选，酶切和PCR鉴定。阳性重组质粒转化到大肠埃希菌BL21（DE3）中，经IPTG诱导，表达产物用SDS-PAGE进行鉴定。大量的表达融合蛋白经纯化和复性后，用Westernblot分析。结果 从弓形虫RH株DNA中扩增出特异的RoP2和P30基因片段，成功克隆出pET-ROP2和pET-P30载体。结论 成功构建了pET-ROP2和pET-P30重组体，获得纯化和复性的弓形虫ROP2和P30的高效表达产物，为弓形虫病的诊断和疫苗研究奠定了基础。     

携带幽门螺杆菌hpaA基因减毒鼠伤寒沙门疫苗菌的构建

构建携带幽门螺杆菌（H.pylori)hpaA基因的重组活减毒鼠伤沙门疫苗菌。方法：用分子生物学方法将hpaA基因克隆入原核表达质粒pTrc99A,并进行核苷酸测序,重组质粒经再导入活减毒鼠伤寒沙门菌SL3261,提取重组菌苗质粒,聚合酶链反应（PCR）和酶切鉴定,筛选目的克隆。结果：经PCR和酶切证实,构建了携带hpaA基因（560bp)的重组核表达质粒pTrc99A-hpaA,并将后者成功转化活减毒鼠伤寒沙门菌SL3261。结论：S我建并鉴定了携带H.pylorihpaA基因的重组活减毒鼠伤寒沙门疫苗菌,为探索制备H.ylori口服份活疫苗奠定了基础。     

携带幽门螺杆菌热休克蛋白B亚单位基因重组活减毒鼠伤寒沙门疫苗菌的构建和鉴定

背景：幽门螺杆菌(h.pylori)是慢性活动性胃炎和消化性溃疡的重要致病菌，以减毒鼠伤寒沙门菌为载体构建活疫苗己成为探索新型H．pylori疫苗的重要途径。目的：构建携带H．pylori热休克蛋白B亚单位(hspB)基因的重组活减毒鼠伤寒沙门疫苗菌。方法：应用基因工程技术将1640bp的hspB基因克隆入原核表达质粒pTrc99A。对重组质粒进行序列测定，并将测序结果与基因文库中H.pylori-hspB的基因和蛋白序列进行BLAST分析，再将重组质粒导入活减毒鼠伤寒沙门菌SL3261。结果：重组质粒经聚合酶链反应(PCR)和双酶切，证实构建了携带hspB基因的重组原核表达质粒pTrc99A—hspB，后者成功转化活减毒鼠伤寒沙门菌SL3261。所构建的重组质粒pTrc99A—hspB中所含的H.pylori-hspB与基因文库中量H.pylori-hspB基因和蛋白的同源性均为97％。结论：成功构建并鉴定了携带量H.pylori-hspB基因的重组活减毒鼠伤寒沙门疫苗菌，为研制H.pylori口服疫苗奠定了基础。     

弓形虫棒状体蛋白2和膜表面蛋白1融合基因的克隆与表达

目的 进行弓形虫棒状体蛋白2（ROP2）和膜表面蛋白1（P30）融合基因的克隆与表达，为弓形虫ROP2?鄄P30基因工程复合抗原的制备做准备。 方法 半套式PCR扩增编码弓形虫P30的基因片段，克隆至已构建成功的重组质粒pUC119/ROP2中，经PCR和酶切鉴定正确的重组质粒pUC119/ROP2-P30再以SacⅠ/HindⅢ双酶切克隆至表达载体pET28b上，鉴定正确的重组质粒pET28b/ROP2-P30转化大肠埃希菌表达菌株BL21-Codon Plus（DE3）-RIL，经异丙基-β-D-硫代半乳糖苷（IPTG）诱导表达。 结果 从弓形虫RH株基因组DNA中扩增出700 bp P30基因片段，成功构建重组质粒pET28b/ROP2-P30，该质粒经PCR和酶切鉴定，与预期结果一致，并在大肠埃希菌中高效表达，产生相对分子质量（Mr）约为 69 000的重组目的蛋白。 结论 弓形虫ROP2和P301融合基因克隆成功，并表达出预期的复合重组蛋白ROP2-P30。     

恙虫病东方体Karp株56kDa与47kDa外膜蛋白基因的嵌合和嵌合基因在大肠杆菌的表达

目的　将恙虫病东方体 (Orientiatsutsugamushi,Ot)Karp株的 5 6kDa和 4 7kDa外膜蛋白基因嵌合 ,并使嵌合基因在大肠杆菌细胞内表达 ,产生双抗原融合蛋白。方法　采用PCR方法 ,从OtKarp株基因组DNA中扩增 5 6kDa蛋白基因片段 ,将该片段分别与原核表达载体pQE30及 4 7kD蛋白基因重组质粒 pQE30 / 4 7连接 ,构建 pQE30 / 5 6及pQE30 / 5 6 - 4 7重组质粒 ;用IPTG诱导转入大肠杆菌内的重组质粒的目的基因表达。结果　SDS -PAGE显示 ,pQE30 / 5 6转化的大肠杆菌产生一约 4 5kDa的融合蛋白和 pQE30 / 5 6 - 4 7转化大肠杆菌产生一约 90kDa融合蛋白 (5 6 - 4 7融合蛋白 ) ,免疫印迹分析显示两融合蛋白均与OtKarp株感染鼠血清产生特异性反应 ,5 6 - 4 7融合蛋白分别与 4 7kDa、5 6kDa重组蛋白免疫的小鼠血清产生特异性反应 ,以及 5 6 - 4 7融合蛋白免疫血清与 5 6kDa和 4 7kDa重组蛋白反应。结论　OtKarp株的 5 6kDa与 4 7kDa外膜蛋白基因嵌合后在大肠杆菌细胞内实现了表达 ,表达的融合蛋白具有 5 6kDa和 4 7kDa外膜蛋白的抗原特性。     

A study of recombinant protective H.pylori antigens

AIM: To construct a recombinant vector which can express M (r)26000 outer membrane protein (OMP) from Helicobacter pylori (Hp), and to obtain the vaccine protecting against Hp infection and a diagnostic reagent kit quickly detecting Hp infection. METHODS: The gene encoding the structural M(r)26000 outer membrane protein of Hp was amplified from Hp chromosomal DNA by PCR, and inserted in the prokaryotic expression vector pET32a (+), which was transformed into the Top10 E. coli strain. Recombinant vector was selected, identified and transformed into BL-21(DE3) E. coli strain. The recombinant fusion proteins were expressed. The antigenicity of recombinant protein was studied by ELISA or immunoblotting and immunized Balb/c mice. RESULTS: The gene of M(r)26000 OMP was amplified to be 594 base pairs, 1.1% of the cloned genes was mutated and 1.51% of amino acid residues was changed, but there was homogeneity between them. The recombinant fusion protein encoded objective polypeptides of 198 amino acid residues, corresponding to calculated molecular masses of M (r)26000. The level of soluble expression products was about 38.96% of the total cell protein. After purification by Ni-NTA agarose resin columniation, the purity of objective protein became about 90%. The ELISA results showed that recombinant fusion protein could be recognized by patient serum infected with Hp and rabbit serum immunized with the recombinant protein. Furthermore,Balb/c mice immunized with the recombinant protein were protected against H.pylori infection. CONCLUSION: M (r)26000 OMP may be a candidate vaccine preventing Hp infection.     

Construction of an attenuated Salmonella typhimurium vaccine carrying the Helicobacter pylori hpaA gene

OBJECTIVE : Helicobacter pylori is documented to have infected more than half of the world’s population. It colonizes the human stomach and is associated with the development of chronic active gastritis, peptic ulcer disease, gastric adenocarcinoma and gastric mucosa‐associated lymphoid tissue (MALT) lymphoma. Immunization against this bacterium represents a cost‐effective strategy to reduce global gastric cancer rates and would have a major impact on H. pylori‐related peptic ulcer disease. HpaA, a subunit protein of H. pylori adhesin, is known to be the pathogenic factor and attenuated Salmonella typhimurium is a live vaccine vector. The present study aimed at constructing and identifying a live attenuated S. typhimurium vaccine carrying the hpaA gene of H. pylori. METHODS : The hpaA gene was amplified from H. pylori genomic DNA by polymerase chain reaction (PCR) and cloned into the NcoI‐SalI site of the prokaryotic expression plasmid pTrc99A. After sequence analysis of the hpaA gene, the identified recombinant plasmid was then used to transform a live attenuated S. typhimurium, namely SL3261, and positive clones were screened by PCR and restriction enzyme digestion. RESULTS : Confirmed by PCR, restriction enzyme digestion and sequence analysis, a recombinant prokaryotic expression plasmid, namely pTrc99A‐hpaA, harboring approximately 560 bp hpaA was constructed and the recombinant plasmid was then successfully introduced into a live attenuated S. typhimurium SL3261. CONCLUSION : A recombinant live attenuated S. typhimurium vaccine harboring the H. pylori hpaA gene was constructed and identified. This work will help develop an oral recombinant live vaccine against H. pylori infection.     

幽门螺杆菌融合蛋白HspA-UreB在大肠杆菌中的表达与鉴定

目的在大肠杆菌中表达幽门螺杆菌(简称Hp)HspA-UreB融合蛋白,并探索其免疫反应性,为Hp基因工程疫苗的研制奠定基础。方法用PCR方法扩增郑州分离Hp菌株MEL-HP27的hspA和ureB基因,分别克隆入pNEB193中。测序后,回收两种基因片段,并以hspA-ureB的顺序连接插入原核表达载体pMAL-C2x进行融合表达。采用蛋白印迹法对表达产物进行鉴定。结果特异PCR法和酶切鉴定证实融合基因hspA-ureB克隆入表达载体中;重组质粒转化大肠杆菌TB1后,经IPTG诱导3h,SDS-PAGE电泳显示在119kDa处出现一条特异蛋白带,即麦芽糖结合蛋白(MBP)与HspA-UreB的融合表达形式,约占细菌总体蛋白含量的31%;该融合蛋白与Hp免疫小鼠血清和Hp阳性病人血清的Westernblot分析结果显示,在119kDa处出现特异杂交带。结论成功地在大肠杆菌中实现了Hp融合蛋白HspA-UreB的高效表达,并证实其具有良好的免疫反应性。     

Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori

AIM: To construct a recombinant vector which can express outer membrane protein (OMP) with Mr18 000 and heat shock protein A (HspA) from Helicobacter pylori(H.pylori)in E.coli BL21, and to exploit the possibility for obtaining the vaccine conferring protection from H. pylori infection.METHODS: The target gene of HspA was amplified from H.pylori chromosome by PCR, and then inserted into the prokaryotic expression vector pET32a (+) by restrictive endonuclease enzyme kpn Ⅰ, BamH Ⅰ simultaneously. The recombinant vector was used to sequence, and then together with pET32a (+)/Omp18, digested by restrictive endonuclease enzyme Hind Ⅲ and BamH Ⅰ simultaneously. pET32a(+)/HspA and Omp18 were recovered from 1% agarose gel by gel kit, and ligated with T4 ligase by BarmH Ⅰ digested viscidity end. The recombinant plasmid of pET32a(+)/HspA/Omp18 was transformed and expressed in E. coli BL21 (DE3) under induction of IPTG. After purification, its antigenicity of the fusion protein was detected by Western blot.RESULTS: Enzyme digestion analysis and sequencing showed that the target genes were inserted into the recombinant vector, composed of 891 base pairs, encoded objective polypeptides of 297 amino acid residues. Compared with GenBank reported by Tomb et al, there were 1.3 %and 1.4 % differences in obtained H. pylori nucleotide sequence and amino acid residues, respectively. SDS-PAGE analysis showed that relative molecule mass (Mr) of the expressed product was Mr 51 000,Mr of protein expressed by pET32a (+) was about Mr 20 000, and soluble expression product accounted for 18.96 % of total bacterial protein.After purification with Ni+2-NTA agarose resins, the purification of recombinant fusion protein was about 95 %. Western blot showed that recombinant fusion protein could be recognized by the patients′ serum infected with H. pylori and anti-Omp18 monoclone, suggesting that this protein had good antigenicity.CONCLUSION: The gene coding for H. pylori Mr18 000OMP and HspA was cloned and expressed successfully. The results obtained lay the foundation for development of H.pylori protein vaccine and a quick diagnostic kit.     

幽门螺杆菌Mr26000外膜蛋白真核载体的构建及表达蛋白的鉴定

目的　构建含人幽门螺杆菌 (Helicobacterpylori,H pylori) 2 6 0 0 0外膜蛋白编码基因的真核重组载体 ,并在COS- 7细胞中表达 ,为核酸疫苗的开发奠定基础。方法　从原核表达质粒 pET32a(+) / 5 94中 ,酶切H pylori 2 6 0 0 0外膜蛋白编码基因片段 ,将目的基因与同样进行酶切、纯化的载体pcDNA3 1进行连接 ,而后转化并筛选含有目的基因的重组载体pcDNA3 1/ 5 94 ,并在COS - 7细胞中表达 ,以RT -PCR ,Dotblot法检测其表达产物。 结果　经酶切证实插入的基因片段为H pylori 2 6 0 0 0外膜蛋白编码基因 ;采用RT -PCR方法 ,能够从转染COS - 7细胞中扩增出一条与目的基因大小一致的DNA片段 ;同时Dotblot法等检测显示 ,该重组质粒能够在COS - 7细胞中表达目的蛋白。结论　成功地构建了真核重组载体 pcDNA3 1/ 5 94 ,并在COS - 7细胞中表达 ,为H pylori核酸疫苗的研制奠定了良好的基础。     

Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity

INTRODUCTION The discovery of H pylori has brought about a revolution in the research of etiological factors of gastrointestinal diseases[1]. It has been confirmed that H pylori is the main cause of chronic superficial gastritis, chronic active gastritis …     

幽门螺杆菌尿素酶B亚单位在大肠杆菌中的融合表达与鉴定

目的 通过对幽门螺杆菌（Helicobacter pylori,Hipylori)尿素酶B亚单位在大肠杆菌中表达的研究，探索其免疫反应性。方法 用高保真PCR方法扩增H.pylori ureB基因，并定向克隆人pNEB193中，然后经酶切回收后插入原核表达载体pMAL-C2X进行融合表达。采用蛋白印迹法对表达产物进行鉴定。结果 特异PCR和酶切鉴定证实融合基因ureB克隆人表达载体，SDS-PAGE结果显示ureB在大肠杆菌中以融合蛋白形式MBP-ureB高效表达，约占细胞总蛋白量的26.7%。该融合蛋白可与H.pylori阳性病人血清发生特异反应。结论 成功构建了高效表达H.pylori ureB的重组菌，为Hp基因工程疫苗的进一步研究奠定了基础。